RecruitingPhase 3NCT05707442

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)


Sponsor

Beijing Tiantan Hospital

Enrollment

74 participants

Start Date

Feb 16, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to assess the efficacy of stent implantation versus medical therapy on idiopathic intracranial hypertension with venous sinus stenosis.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two treatments for a condition called idiopathic intracranial hypertension (IIH) — where pressure inside the skull is too high without a known cause — specifically in patients who also have a narrowing in a brain vein (venous sinus stenosis): placing a stent to open the narrowed vein versus continuing with medications alone. **You may be eligible if...** - You have had a confirmed diagnosis of IIH for more than 2 months - Your spinal fluid pressure was 250 mmH₂O or higher within the past 6 weeks - Brain imaging shows no other cause for the high pressure - You have a significant narrowing in a brain vein (at least 50%) with a pressure difference across it - At least one eye has papilledema (swelling at the back of the eye from the pressure) and some vision loss - Your vision is above 20/200 **You may NOT be eligible if...** - You have previously had surgery for IIH (shunt, optic nerve surgery, or prior stenting) - You are experiencing rapid vision loss requiring urgent intervention - You have vision problems from causes other than IIH - You have other conditions that affect your ability to participate safely Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREStent Implantation

Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).

DRUGAcetazolamide-based medical therapy

The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.

BEHAVIORALWeight loss

The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.


Locations(1)

Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05707442


Related Trials